Loading…
Loading…
BREMEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search.
BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
On June 15, 2026, Bruker Corp (BRKR) shares rose 4.4% to a current price of $56.63. The stock has shown remarkable performance within the past year, with a 48.7
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Bruker NASDAQ: BRKR is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies healthcare conference.
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for BRKR and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.